問卷

TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

趙祖怡Chao, Tsu-Yi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

篩選

List

106Cases

2020-07-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2014-05-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2019-01-11 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2020-11-18 - 2024-12-31

Phase II

Completed
An Exploratory, Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase IIa Study to Assess the Analgesic Activity of PAX-1 in Patients with Persistent Cancer Pain.
  • Condition/Disease

    Persistent Cancer Pain

  • Test Drug

    PAX-1

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2016-12-29 - 2023-09-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

2023-12-31 - 2026-03-18

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

Terminated1Sites

2020-11-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2026-02-01

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-03-19 - 2026-03-16

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2022-10-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites